Two previous studies successfully developed bifunctional siRNAs that effectively targeted and inhibited BCL-2 and TGF-β while simultaneously activating RIG-I through modification of the triphosphate group at the 5’ end of the siRNA, implementing these modifications to potentiate the anti-tumor effects of the siRNAs [35, 36]. This evidence concerns the gene BCL2 and neoplasm.